Your session is about to expire
← Back to Search
3 Tesla MRI for Bladder Cancer
N/A
Waitlist Available
Led By Michael V. Knopp, MD, PhD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Scheduled for radical cystectomy and lymph node dissection
Known bladder cancer
Must not have
Patient with significant renal insufficiency, i.e. an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m2
Patients with sickle cell anemia and other hemolytic anemia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is studying how well a 3 Tesla MRI works in finding cancer in patients with bladder cancer.
Who is the study for?
This trial is for individuals with confirmed bladder cancer who are scheduled for surgery to remove the bladder and lymph nodes. Participants must be able to consent and have no issues that would prevent them from undergoing an MRI, such as allergies to contrast agents or severe kidney problems.
What is being tested?
The study is evaluating how effective a high-powered 3 Tesla MRI is in detecting bladder cancer compared to standard approaches. Patients will undergo this advanced imaging before their planned surgeries.
What are the potential side effects?
While MRIs don't typically cause side effects, some patients may experience discomfort or anxiety due to the enclosed space of the machine (claustrophobia) or reactions to contrast agents used during the procedure.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for surgery to remove my bladder and nearby lymph nodes.
Select...
I have been diagnosed with bladder cancer.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My kidney function is significantly reduced.
Select...
I have sickle cell anemia or another type of hemolytic anemia.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: MRI+surgery+chemotherapyExperimental Treatment3 Interventions
3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy
Group II: MRI+surgeryExperimental Treatment2 Interventions
3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
chemotherapy
2002
Completed Phase 3
~2660
Find a Location
Who is running the clinical trial?
University of CincinnatiLead Sponsor
438 Previous Clinical Trials
638,590 Total Patients Enrolled
Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
293,212 Total Patients Enrolled
Michael V. Knopp, MD, PhDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center